Active Implantable Medical Devices Market Size
|Study Period||2018 - 2028|
|Base Year For Estimation||2022|
|Forecast Data Period||2023 - 2028|
|Fastest Growing Market||Asia Pacific|
|Largest Market||North America|
*Disclaimer: Major Players sorted in no particular order
Need a report that reflects how COVID-19 has impacted this market and its growth?
Active Implantable Medical Devices Market Analysis
The active implantable medical devices market is projected to register a CAGR of 7.2% during the forecast period.
The COVID-19 pandemic has had a large impact on the creation and use of medical devices, as well as most aspects of healthcare. Patients with cardiac implantable electronic devices (CIED) declined scheduled follow-up appointments during the global COVID-19 pandemic due to the risk of infection. Remote monitoring is intended to optimize the clinical treatment of CIED patients, enhance their quality of life, and decrease access to emergency rooms and hospitals. As per an article titled “Implantation of cardiac electronic devices in active COVID-19 patients: Results from an international survey” published in February 2022, in hospitals around the world, Cardiac implantable electronic device (CIED) procedure rates for known active COVID-19 disease ranged from 0 to 16.2 per 1000 patients. High rates of complications and mortality were observed in patients with active COVID-19 infection who had CIED implantation. Before performing CIED implantation in patients with active COVID-19, operators should weigh these risks. These abovementioned factors are expected to have a significant impact on the growth of the market growth during and after the post-pandemic.
Certain factors that are driving the market growth include the increasing burden of cardiovascular and neurological diseases and investments and funds to develop technologically advanced products. As per an article titled “The prevalence and predictors of cardiovascular diseases in Kherameh cohort study: a population-based study on 10,663 people in southern Iran” published in, the prevalence of Cardiovascular Disease (CVD) increased from 257 million in 1990 to 550 million in 2020. Evidence has also indicated the global prevalence of angina to be 0.73–14.4% in females and 0.76–15.1% amongst males. The market for implantable devices is expected to grow due to several factors, including an aging population, an increase in cardiovascular and neurological diseases, investments in developing technologically advanced products, expanded uses for neurostimulators, and favorable reimbursement conditions for ENT procedures in developed nations.
Furthermore, increasing chronic diseases coupled with the advancements in active implantable medical devices are projected to boost market growth. As per an article titled “Commentary on Chronic Disease Prevention in 2022” published in 2022, nearly 60% of adult Americans have at least one chronic disease. Chronic conditions like diabetes, cancer, and cardiovascular disease are the leading causes of death in the United States.
Product approvals and launches are expected to boost the market growth. For instance, in December 2021, LifeTech Scientific Corporation extended its agreements with Medtronic to further the strategic collaboration on the "HeartTone domestic pacemaker project" and to start the collaboration on domestically-made MRI-conditional pacemakers. Additional to that, in February 2021, Boston Scientific Corporation initiated the MODULAR ATP clinical trial to evaluate the safety, performance and effectiveness of the mCRM Modular Therapy System. The mCRM system consists of two cardiac rhythm management (CRM) devices intended to work together to coordinate therapy: the EMBLEM MRI subcutaneous implantable defibrillator system and the empower modular pacing system (MPS), which is designed to be the one of the first leadless pacemaker capable of delivering both bradycardia pacing support and antitachycardia pacing (ATP).
However, rising demand for non-invasive procedures, issues related to implantable devices, and the high cost of the devices are anticipated to impede market growth.
Active Implantable Medical Devices Market Trends
This section covers the major market trends shaping the Active Implantable Medical Devices Market according to our research experts:
Implantable Cardiac Pacemaker is Expected to Witness Healthy Growth Over the Forecast Period
The implantable cardiac pacemakers are of three major types, namely, single-chamber, dual-chamber, and biventricular pacemakers. The growth of the segment can be attributed to factors, such as reduced post-surgical complications and the presence of multiple leads to assure normal physiology of the heart.
According to an article titled “Heart-disease risk soars after COVID — even with a mild case” published in February 2022, for at least a year following diagnosis, even a minor case of COVID-19 can raise a person's risk of cardiovascular issues. Over the year following infection, people who had recovered from COVID-19 exhibited substantial increases in 20 cardiovascular issues. In the COVID-19 group, there were approximately 12 additional cases of heart failure per 1,000 study participants, or a 72% increase in risk. These factors are expected to accelerate the usage of implantable cardiac pacemakers and drive segmental growth in the market. As per an article titled “Pacemaker” published in May 2022, between 500,000 and 3 million Americans have pacemakers implanted. With age, the likelihood of pacemaker insertion drastically rises. In actuality, patients over the age of 65 receive more than 70% of all pacemaker implantations.
Various product launches are expected to accelerate the segmental growth in the market. for instnace, in June 2021, Medtronic Private Limited, India, announced the launch of Micra AV - a miniaturize ully self-contained pacemaker that delivers advanced pacing technology to atrioventriculor (AV) block patients by minimally invasive approach.
Thus, the above-mentioned factors and the increasing usage of implantable cardiac pacemakers is expected to drive segmental growth in the market.
To understand key trends, Download Sample Report
North America Dominates the Market and Expected to do Same Over the Forecast Period
North America is expected to hold a significant share in the market and is expected to do the same in the forecast period.
The rising prevalence of cardiovascular diseases, high obesity rates, and favorable reimbursement environments are the primary factors that are driving the market growth. A few of the key market players in the country are developing novel products that are expected to promote the market in the region. For instance, in February 2020, Mexico joined the HEARTS initiative to strengthen primary healthcare for Cardiovascular Diseases. Promoted by the Pan American Health Organization/World Health Organization (PAHO/WHO), the initiative aims to improve the prevention and control of hypertension at the primary care level. Thus, owing to the abovementioned factors, the studied market in the country is expected to register significant growth over the forecast period.
According to the Centers for Disease Control and Prevention (CDC)’s article titled "Heart Disease Facts", updated in September 2020, heart disease is the leading cause of death in the United States. The same source also reports that every year, about 805,000 Americans have a heart attack. As per Centers for Disease Control and Prevention (CDC) statistics, more than three million people in the United States suffer from atrial fibrillation, which is the most common type of abnormal heart rhythm. Furthermore, the number is expected to quadruple by 2050, as the population ages. Therefore, the increasing burden of cardiovascular diseases is expected to accelerate the demand for the market in the region during the forecast period.
As per an article titled "Prevalence and treatment of neuropathic pain diagnoses among U.S. nursing home residents" published in July 2022, the prevalence of neuropathic pain was 14.6% in the United States. Thus, the high incidence of neuropathic pain is also one of the reasons expected to drive the market in the region. The rise in cases of failed back surgery syndrome (FBSS), patients with neuropathic pain, and efforts to manage chronic neuropathic pain with methods other than chronic opioid therapy have all contributed to the emergence of neurostimulation in the country.
In February 2022, the United States Food and Drug Administration (FDA) approved Abbott’s CardioMEMS HF System to support the care of more people living with heart failure. Such product approvals are also expected to drive market growth in the region
Therefore, the above-mentioned factors are expected to drive market growth in the region during the forecast period.
To understand geography trends, Download Sample Report
Active Implantable Medical Devices Industry Overview
The global active implantable medical devices market is moderately competitive and consists of a few major players. Companies like Abbott Laboratories, Biotronik Se & Co., Kg, Boston Scientific Corporation, Cochlear Limited, Livanova PLC, Med-EL, Medtronic PLC, Nurotron Biotechnology Co. Ltd., Demant A/S, Sonova Holding AG, Smith & Nephew, Johnson & Johnson Services Inc., and Strykeramong others, hold the substantial market share in the Active Implantable Medical Devices market.
Active Implantable Medical Devices Market Leaders
Boston Scientific Corporation
Biotronik Se & Co., Kg
Nurotron Biotechnology Co. Ltd.
*Disclaimer: Major Players sorted in no particular order
Active Implantable Medical Devices Market News
- In August 2022, Medtronic plc launched an investigational extravascular implantable cardioverter defibrillator (EV ICD) system defibrillator with the lead placed under the breastbone, outside of the heart and veins achieved a defibrillation success rate of 98.7%, and met its safety endpoints in a global clinical trial.
- In February 2022, Abbott launched the patient implants of a dual-chamber leadless pacemaker system as part of its AVEIR DR i2i pivotal clinical study. The implant of Abbott's investigational aveir dual-chamber leadless pacemaker represents a significant technological milestone for leadless pacing technology and is the first to occur around the world within the pivotal trial.
Active Implantable Medical Devices Market Report - Table of Contents
1.1 Study Assumptions and Market Definitions
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Burden of Cardiovascular and Neurological Diseases
4.2.2 Investments and Funds to Develop Technologically Advanced Products
4.3 Market Restraints
4.3.1 Issues Related to the Use of Implantable Medical Devices
4.3.2 High Cost of Implants and Stringent Regulations
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - in USD million)
5.1 By Product
5.1.1 Implantable Cardioverter Defibrillators
5.1.2 Implantable Cardiac Pacemakers
5.1.3 Ventricular Assist Devices
5.1.4 Implantable Heart Monitors/Insertable Loop Recorders
5.1.6 Implantable Hearing Devices
5.2.1 North America
188.8.131.52 United States
184.108.40.206 United Kingdom
220.127.116.11 Rest of Europe
18.104.22.168 South Korea
22.214.171.124 Rest of Asia-Pacific
5.2.4 Middle East and Africa
126.96.36.199 South Africa
188.8.131.52 Rest of Middle East and Africa
5.2.5 South America
184.108.40.206 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Biotronik Se & Co., Kg
6.1.3 Boston Scientific Corporation
6.1.4 Cochlear Limited
6.1.5 Livanova PLC
6.1.7 Medtronic PLC
6.1.8 Nurotron Biotechnology Co. Ltd.
6.1.9 Sonova Holding AG
6.1.10 Smith & Nephew
6.1.11 Johnson & Johnson Services Inc.
6.1.12 Stryker Corporation
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Active Implantable Medical Devices Market Research FAQs
What is the current Global Active Implantable Medical Devices Market size?
The Global Active Implantable Medical Devices Market is projected to register a CAGR of 7.2% during the forecast period (2023-2028).
Who are the key players in Global Active Implantable Medical Devices Market?
Abbott Laboratories, Medtronic PLC., Boston Scientific Corporation, Biotronik Se & Co., Kg and Nurotron Biotechnology Co. Ltd. are the major companies operating in the Global Active Implantable Medical Devices Market.
Which is the fastest growing region in Global Active Implantable Medical Devices Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2023-2028).
Which region has the biggest share in Global Active Implantable Medical Devices Market?
In 2023, the North America accounts for the largest market share in the Global Active Implantable Medical Devices Market.
Global Active Implantable Medical Devices Industry Report
Statistics for the 2023 Global Active Implantable Medical Devices market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Global Active Implantable Medical Devices analysis includes a market forecast outlook to 2028 and historical overview. Get a sample of this industry analysis as a free report PDF download.